15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau

Christian Winther Eskelund,Arne Kolstad,Mats Jerkeman,Riikka Räty,Anna Laurell,Sandra Eloranta,Karin E. Smedby,Simon Husby,Lone Bredo Pedersen,Niels S. Andersen,Mikael Eriksson,Eva Kimby,Hans Bentzen,Outi Kuittinen,Grete F. Lauritzsen,Herman Nilsson-Ehle,Elisabeth Ralfkiaer,Mats Ehinger,Christer Sundström,Jan Delabie,Marja-Liisa Karjalainen-Lindsberg,Christopher T. Workman,Christian Garde,Erkki Elonen,Peter de Nully Brown,Kirsten Grønbæk,Christian H. Geisler

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau

2016

In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-t ...

Keywords:

Immunology
Clinical trial
Transplantation
Multicenter trial
Medicine
Bendamustine
Rituximab
Methotrexate
Cytarabine
Mantle cell lymphoma
Hematology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

102

Citations